Search
Displaying results 201 to 210 of 615.
Making sure that antibiotics will still be effective in the future
The WASA project runs continued education seminars which address topics such as "Guideline-based antibiotics management of upper and lower airway and urinary tract infections by general practitioners". The training sessions were developed by the Hygienenetzwerk…
Potential new drugs from previously unknown tropical fungus
Fungi are playing a crucial role in the search for new active compounds: As a rich source of metabolic products with selective biological activity, they can be used for the development of new drugs. The so-called mycobiota of tropical countries offers a great potential…
Medicine Maker honours HIPS researcher
Lehr is the head of the "Drug Delivery" department at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS). His research focuses on the tailor-made transport of medications through the biological barriers of the body to their site of action. The "Top 100"…
New actors identified in atherosclerosis
Atherosclerosis is the most common cause of death and disease in the Western world. In Germany, about 300,000 people each year suffer a heart attack and some 270,000 a stroke as a result of the condition. Atherosclerosis is estimated to be responsible for a little more…
A common European strategy against COVID-19
Control of the coronavirus pandemic by vaccines, which are currently close to approval, is not expected until later in 2021. Until then, SARS-CoV-2 case numbers must be controlled through non-pharmaceutical measures such as contact reductions, hygiene measures and case…
Corona: How the virus interacts with cells
In the biosafety level 3 suite at HIRI, the scientists infected human cells with the new coronavirus, which uses RNA as genetic material. In a second step, they purified the viral RNA and identified the proteins bound to it. "Mass spectrometry allows us to accurately…
Leibniz Prize 2021 for Rolf Müller
“I am very pleased about the great honour for Rolf Müller and the recognition of his many years of research work. I would like to congratulate him very warmly on behalf of the entire HZI,” said Prof Dirk Heinz, Scientific Director of the HZI. “Rolf Müller is one of the…
Federal government decides on million-euro funding for HIPS
The Federal Budget Committee has assured the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) funding of 47 million euros for the further expansion of the institute. Together with funds from the state of Saarland, the HIPS will receive a total of 70…
Important step in fighting resistant bacteria
Its metabolism and the structure of its cellular membrane render the hospital germ Pseudomonas aeruginosa resistant against several antibiotics. P . aeruginosa is responsible for around ten percent of all hospital infections, making it one of the most common…
Two HZI scientists honoured as “Highly-cited researchers”
Prof Jörg Vogel is founding director of the Helmholtz Institute for RNA-based Infection Research (HIRI), a site of the Helmholtz Centre for Infection Research (HZI) with the Julius-Maximilians-Universität Würzburg (JMU). His research group “RNA biology of bacterial…
